论文部分内容阅读
纤溶功能损害在高血压和糖尿病患者动脉粥样硬化血栓形成事件中起着一定的作用。血管紧张素转换酶抑制剂和钙拮抗剂可以调节纤溶过程,为评价这些药物对纤溶酶原激活物抑制剂-1(PAI-1)的作用,作者进行了随机对照试验。 方法 在给予4周安慰剂之后,患有高血压和2型糖尿病的患者(共有96例,51％为黑人)被随机双盲分为福辛普利20mg或40mg/d组及氨氯地平5mg或10mg/d组,固定剂量给予4周。再经给予4周安慰剂洗脱期后,交叉治疗进行4周。
Fibrinolytic impairment plays a role in atherothrombotic events in patients with hypertension and diabetes. Angiotensin-converting enzyme inhibitors and calcium antagonists regulate the fibrinolytic process. To assess the effect of these drugs on plasminogen activator inhibitor-1 (PAI-1), the authors conducted randomized controlled trials. Methods After 4 weeks of placebo, patients with hypertension and type 2 diabetes (96 in total, 51% in black) were randomized to double-blind fosinopril 20 mg or 40 mg / d and amlodipine 5 mg Or 10 mg / d group, given a fixed dose for 4 weeks. After four weeks of placebo elution, crossover treatment was performed for 4 weeks.